-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DAC-002 in Small-Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DAC-002 in Small-Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DAC-002 in Small-Cell Lung Cancer Drug Details: DAC-002 is under development...
-
Product Insights
Mild Cognitive Impairment – Drugs In Development, 2023
Global Markets Direct’s, ‘Mild Cognitive Impairment - Drugs In Development, 2023’, provides an overview of the Mild Cognitive Impairment pipeline landscape. The report provides comprehensive information on the therapeutics under development for Mild Cognitive Impairment, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Cognitive Impairment – Drugs In Development, 2023
Global Markets Direct’s, ‘Cognitive Impairment - Drugs In Development, 2023’, provides an overview of the Cognitive Impairment pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cognitive Impairment, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Frontotemporal Dementia (FTD) – Drugs In Development, 2023
Global Markets Direct’s, ‘Frontotemporal Dementia (FTD) - Drugs In Development, 2023’, provides an overview of the Frontotemporal Dementia (FTD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Frontotemporal Dementia (FTD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Progressive Supranuclear Palsy – Drugs In Development, 2023
Global Markets Direct’s, ‘Progressive Supranuclear Palsy - Drugs In Development, 2023’, provides an overview of the Progressive Supranuclear Palsy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Progressive Supranuclear Palsy , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally,...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – (Sodium Phenylbutyrate + Taurursodiol) in Progressive Supranuclear Palsy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Sodium Phenylbutyrate + Taurursodiol) in Progressive Supranuclear Palsy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Sodium Phenylbutyrate + Taurursodiol) in Progressive Supranuclear Palsy...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Sodium Phenylbutyrate + Taurursodiol) in Alzheimer’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Sodium Phenylbutyrate + Taurursodiol) in Alzheimer's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.(Sodium Phenylbutyrate + Taurursodiol) in Alzheimer's Disease Drug Details:Sodium phenylbutyrate...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CHM-0201 in Refractory Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CHM-0201 in Refractory Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.CHM-0201 in Refractory Chronic Lymphocytic Leukemia (CLL) Drug Details:CHM-0201 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Alisertib in Atypical Teratoid Rhabdoid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Alisertib in Atypical Teratoid Rhabdoid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Alisertib in Atypical Teratoid Rhabdoid Tumor Drug Details: Alisertib (MLN-8237)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Sodium Phenylbutyrate + Taurursodiol) in Mild Cognitive Impairment
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Sodium Phenylbutyrate + Taurursodiol) in Mild Cognitive Impairment report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.(Sodium Phenylbutyrate + Taurursodiol) in Mild Cognitive ImpairmentDrug Details:Sodium...